Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Urology Section, Minneapolis VA Health Care System, Minneapolis, Minnesota, USA.
Cochrane Database Syst Rev. 2023 Nov 13;11(11):CD013445. doi: 10.1002/14651858.CD013445.pub2.
Kidney stones (also called renal stones) can be a source of pain, obstruction, and infection. Depending on size, location, composition, and other patient factors, the treatment of kidney stones can involve observation, shock wave lithotripsy, retrograde intrarenal surgery (RIRS; i.e. ureteroscopic approaches), percutaneous nephrolithotomy (PCNL), or a combination of these approaches.
To assess the effects of percutaneous nephrolithotomy (PCNL) versus retrograde intrarenal surgery (RIRS) for the treatment of renal stones in adults.
We performed a comprehensive search of the Cochrane Library, MEDLINE, Embase, Scopus, and two trials registries up to 23 March 2023. We applied no restrictions on publication language or status.
We included randomized controlled trials that evaluated PCNL (grouped by access size in French gauge [Fr] into three groups: ≥ 24 Fr [standard PCNL], 15-23 Fr [mini-PCNL and minimally invasive PCNL], and < 15 Fr [ultra-mini-, mini-micro-, super-mini-, and micro-PCNL]) versus RIRS.
Two review authors independently selected studies and extracted data from the included studies. Our primary outcomes were stone-free rate, major complications, and need for secondary interventions. Our main secondary outcomes were unplanned medical visits to emergency/urgent care or outpatient clinic, length of hospital stay, ureteral stricture or injury, and quality of life. We performed statistical analyses using a random-effects model. We rated the certainty of evidence using GRADE criteria. We adopted a minimally contextualized approach with predefined thresholds for minimal clinically important differences (MCIDs).
We included 42 trials assessing the effects of PCNL versus RIRS in 4571 randomized participants. Twenty-two studies were published as full-text articles, and 20 were published as abstract proceedings. The average size of stones ranged from 10.1 mm to 39.1 mm. Most studies did not report sources of funding or conflicts of interest. The main results for the most important outcomes are summarized below. Stone-free rate PCNL compared with RIRS may improve stone-free rates (risk ratio [RR] 1.13, 95% confidence interval [CI] 1.08 to 1.18; I = 71%; 39 studies, 4088 participants; low-certainty evidence). Based on 770 participants per 1000 being stone-free with RIRS, this corresponds to 100 more (62 more to 139 more) stone-free participants per 1000 with PCNL (an absolute difference of 10%, where the predefined MCID was 5%). Major complications PCNL compared with RIRS probably has little or no effect on major complications (RR 0.86, 95% CI 0.59 to 1.25; I = 15%; 34 studies, 3649 participants; moderate-certainty evidence). Based on 31 complications in the RIRS group, this corresponds to six fewer (13 fewer to six more) major complications per 1000 with PCNL (an absolute difference of 0.6%, where the predefined MCID was 2%). Need for secondary interventions PCNL compared with RIRS may reduce the need for secondary interventions (RR 0.31, 95% CI 0.17 to 0.55; I = 61%; 21 studies, 2005 participants; low-certainty evidence). Based on 222 secondary interventions in the RIRS group, this corresponds to 153 fewer (185 fewer to 100 fewer) secondary interventions per 1000 with PCNL (an absolute difference of 15.3%, where the predefined MCID was 5%). Unplanned medical visits No studies reported unplanned medical visits. Length of hospital stay PCNL compared with RIRS may extend length of hospital stay (mean difference 1.04 days more, 95% CI 0.27 more to 1.81 more; I = 100%; 26 studies, 2804 participants; low-certainty evidence). This effect size is greater than the predefined MCID of one day. Ureteral stricture or injury PCNL compared with RIRS may have little or no effect on the occurrence of ureteral strictures (RR 0.93, 95% CI 0.39 to 2.21; I = 0%; 13 studies, 1574 participants; low-certainty evidence). Based on 14 ureteral strictures in the RIRS group, this corresponds to one fewer (nine fewer to 17 more) ureteral strictures per 1000 with PCNL (an absolute difference of 0.1%, where the predefined MCID was 2%). Quality of life No studies reported quality of life.
AUTHORS' CONCLUSIONS: Based on a large body of evidence from 42 trials, we found that PCNL compared with RIRS may improve stone-free rates and may reduce the need for secondary interventions, but probably has little or no effect on major complications. PCNL compared with RIRS may have little or no effect on ureteral stricture rates and may increase length of hospital stay. We found no evidence on unplanned medical visits or participant quality of life. Because of the considerable shortcomings of the included trials, the evidence for most outcomes was of low certainty. Access size for PCNL was less than 24 Fr in most studies that provided this information. We expect the findings of this review to be helpful for shared decision-making about management choices for individuals with renal stones.
肾结石(也称为肾石)可能是疼痛、梗阻和感染的根源。根据结石的大小、位置、成分和其他患者因素,肾结石的治疗可能包括观察、体外冲击波碎石术、逆行肾盂内手术(即输尿管镜方法)、经皮肾镜取石术(PCNL)或这些方法的联合治疗。
评估经皮肾镜取石术(PCNL)与逆行肾盂内手术(RIRS)治疗成人肾结石的效果。
我们全面检索了 Cochrane 图书馆、MEDLINE、Embase、Scopus 和两个试验注册库,检索时间截至 2023 年 3 月 23 日。我们对发表语言或状态没有任何限制。
我们纳入了评估 PCNL(按法国 gauge [Fr] 分为三组:≥24 Fr [标准 PCNL]、15-23 Fr [迷你-PCNL 和微创 PCNL] 和 < 15 Fr [超迷你、迷你微、超级迷你和微 PCNL])与 RIRS 的随机对照试验。
两名综述作者独立选择研究并从纳入的研究中提取数据。我们的主要结局是结石清除率、主要并发症和需要二次干预。我们的主要次要结局是无计划的医疗就诊于急诊/紧急护理或门诊、住院时间、输尿管狭窄或损伤以及生活质量。我们使用随机效应模型进行统计分析。我们使用 GRADE 标准评定证据确定性。我们采用了一种最小语境化的方法,设定了最小临床重要差异(MCID)的预设阈值。
我们纳入了 42 项比较 PCNL 与 RIRS 治疗 4571 名随机参与者的试验。22 项研究以全文文章的形式发表,20 项研究以摘要会议记录的形式发表。石头的平均大小范围从 10.1 毫米到 39.1 毫米。大多数研究没有报告资金来源或利益冲突。以下是最重要结果的主要结果总结。
结石清除率 PCNL 与 RIRS 相比,可能会提高结石清除率(风险比 [RR] 1.13,95%置信区间 [CI] 1.08 至 1.18;I = 71%;39 项研究,4088 名参与者;低确定性证据)。根据 RIRS 每 1000 名患者中有 100 名结石清除者,这相当于每 1000 名患者中有 100 名(62 名至 139 名)更多的 PCNL 患者结石清除(绝对差异 10%,其中预定义的 MCID 为 5%)。
主要并发症 PCNL 与 RIRS 相比,可能对主要并发症的影响较小或没有影响(RR 0.86,95%置信区间 [CI] 0.59 至 1.25;I = 15%;34 项研究,3649 名参与者;中等确定性证据)。根据 RIRS 组的 31 种并发症,这相当于 PCNL 组每 1000 名患者中减少 6 种(13 种至 6 种)主要并发症(绝对差异 0.6%,其中预定义的 MCID 为 2%)。
需要二次干预 PCNL 与 RIRS 相比,可能会减少需要二次干预的次数(RR 0.31,95%置信区间 [CI] 0.17 至 0.55;I = 61%;21 项研究,2005 名参与者;低确定性证据)。根据 RIRS 组的 222 次二次干预,这相当于 PCNL 组每 1000 名患者中减少 153 次(185 次至 100 次)二次干预(绝对差异 15.3%,其中预定义的 MCID 为 5%)。
无计划的医疗就诊没有研究报告无计划的医疗就诊。
住院时间 PCNL 与 RIRS 相比,可能会延长住院时间(平均差异 1.04 天,95%置信区间 [CI] 0.27 天至 1.81 天;I = 100%;26 项研究,2804 名参与者;低确定性证据)。这一效应量大于预定义的 1 天 MCID。
输尿管狭窄或损伤 PCNL 与 RIRS 相比,发生输尿管狭窄的可能性较小或没有影响(RR 0.93,95%置信区间 [CI] 0.39 至 2.21;I = 0%;13 项研究,1574 名参与者;低确定性证据)。根据 RIRS 组的 14 例输尿管狭窄,这相当于 PCNL 组每 1000 名患者中减少 1 例(9 例至 17 例)输尿管狭窄(绝对差异 0.1%,其中预定义的 MCID 为 2%)。
生活质量没有研究报告生活质量。
基于 42 项试验的大量证据,我们发现 PCNL 与 RIRS 相比,可能会提高结石清除率并减少二次干预的需求,但对主要并发症的影响可能较小或没有。PCNL 与 RIRS 相比,对输尿管狭窄的发生率影响较小,可能会延长住院时间。我们没有发现无计划的医疗就诊或参与者生活质量的证据。由于纳入研究存在相当多的缺陷,大多数结局的证据确定性为低。大多数提供这方面信息的研究中,PCNL 的通道尺寸小于 24 Fr。我们预计,本综述的结果将有助于肾结石患者管理方案选择的共同决策。